Based on the UroGen Pharma Ltd stock forecast from 3 analysts, the average analyst target price for UroGen Pharma Ltd is USD 27.33 over the next 12 months. UroGen Pharma Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of UroGen Pharma Ltd is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, UroGen Pharma Ltd’s stock price was USD 9.66. UroGen Pharma Ltd’s stock price has changed by -8.87% over the past week, -20.36% over the past month and -29.64% over the last year.
No recent analyst target price found for UroGen Pharma Ltd
No recent average analyst rating found for UroGen Pharma Ltd
Company Overview UroGen Pharma Ltd
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102, UGN-103 which is in phase 3 of clinical trial for intravesical solution, and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Read Less
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and...Read More
Frequently Asked Questions About UroGen Pharma Ltd (URGN) Stock
Based on ratings from 3 analysts UroGen Pharma Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on URGN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for URGN is USD 27.33 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on URGN's stock to indicate if its overvalued.
The last closing price of URGN's stock was USD 9.66.
The most recent market capitalization for URGN is USD 0.47B.
Based on targets from 3 analysts, the average taret price for URGN is projected at USD 27.33 over the next 12 months.
This means that URGN's stock price may go up by +182.95% over the next 12 months.
We can't find any ETFs which contains UroGen Pharma Ltd's stock.
As per our most recent records UroGen Pharma Ltd has 235 Employees.
UroGen Pharma Ltd's registered address is 400 Alexander Park Drive, Princeton, NJ, United States, 08540.
You can get more information about it from UroGen Pharma Ltd's website at https://www.urogen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About UroGen Pharma Ltd (URGN) Stock
Based on ratings from 3 analysts UroGen Pharma Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on URGN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for URGN is USD 27.33 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on URGN's stock to indicate if its overvalued.
The last closing price of URGN's stock was USD 9.66.
The most recent market capitalization for URGN is USD 0.47B.
Based on targets from 3 analysts, the average taret price for URGN is projected at USD 27.33 over the next 12 months.
This means that URGN's stock price may go up by +182.95% over the next 12 months.
We can't find any ETFs which contains UroGen Pharma Ltd's stock.
As per our most recent records UroGen Pharma Ltd has 235 Employees.
UroGen Pharma Ltd's registered address is 400 Alexander Park Drive, Princeton, NJ, United States, 08540.
You can get more information about it from UroGen Pharma Ltd's website at https://www.urogen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for URGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
